NCT04488770View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

May 14, 2021

Study Completion Date

May 14, 2021

Conditions
Urinary Tract Infections
Interventions
DRUG

GSK3882347

Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

DRUG

Placebo

Matching strength placebo capsules will be provided

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

collaborator

Wellcome Trust

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT04488770 - Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. | Biotech Hunter | Biotech Hunter